Atrial FibrillationAFACARTNCT02113761
Non Invasive Mapping Before Ablation for Atrial Fibrillation.
An observational study of Atrial Fibrillation, run by Brugmann University Hospital at 1 site in Belgium.
Trial summary
RATIONALE / CONTEXT The ECG records the electrical activity propagating along cardiac cells (from the atria to the ventricles). The standard 12 ECG leads placed on the chest measure the global activation of the heart and do not have the ability to detect small-scale disturbances or to pinpoint ectopic activity. Read more about this study
- Who is it for?
- Ages 15 years and olderHealthy volunteers can take part
- Conditions the study is for
- Atrial Fibrillation
- How many people
- 100 participants
- Where
- 1 siteBelgium
- Study dates
- Jan 2014to 21 Dec 2016
- Phase
- Observational
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 15 years and older
- All sexes
- Healthy volunteers accepted
- Child, Adult, Older adult
Study population: Patients with persistent atrial fibrillation as described by the Consensus Statement and with an indication for atrial fibrillation catheter ablation.
Who may be able to join
- Male or Female Adults (≥18 years old)
- Minors (15-18 years) of both sexes subject to parental consent or legal representative
- Persistent AF ablation refractory to drugs
- Persistent AF (as defined by consensus statement) for ≤ 12 month duration
- Consent signed by the patient after reading the information leaflet
Who cannot join
- Any previous left atrial (LA) ablation
- Any previous LA or RA surgery
- Current intra-cardiac thrombus
- Presence of any pulmonary vein stents
- Presence of any pre-existing pulmonary vein stenosis
- Anteroposterior LA diameter > 5.5 cm by TTE or CT
Show all 17Show fewer
- Presence of any cardiac valve prosthesis
- Clinically significant mitral valve regurgitation or stenosis
- Myocardial infarction, PCI / PTCA or coronary artery stenting within the last 3 months
- Unstable angina
- Any cardiac surgery within the last 3 months
- NYHA class III or IV congestive heart failure
- Uncontrolled hyperthyroidism
- Any cerebral ischemic event (strokes or TIAs) which occurred during the 6 months interval preceding the consent Date.
- Life expectancy less than one (1) year
- Current or anticipated participation in any other clinical trial of a drug, device or biologic should be done only after prior consultation and approval of the investigator(s)
- Unwilling or unable to comply fully with study procedures and follow-up
Trial locations and contacts
1 site in 1 country.
About this study
Official title: Non Invasive Mapping Before Ablation for Atrial Fibrillation: the Afacart Study.
RATIONALE / CONTEXT The ECG records the electrical activity propagating along cardiac cells (from the atria to the ventricles). The standard 12 ECG leads placed on the chest measure the global activation of the heart and do not have the ability to detect small-scale disturbances or to pinpoint ectopic activity. By the 1960s, multiple electrodes were placed around the chest to try to understand the complexity of the distribution of electrical activity in relation to the single cardiothoracic geometry of each individual. The safety of this method is similar to the ECG but its superiority has been demonstrated by the detection of anomalies imperceptible to the standard ECG. The accuracy of the technique in localizing rhythm disturbances is on the order of 5 mm.
OBJECTIVES Main objective: To evaluate the utility of noninvasive mapping during persistent AF electrophysiology procedure
Read more
Secondary objectives:
- Compare the effectiveness of noninvasive mapping compared to conventional standard of care methods for AF mapping and ablation procedure.
- Evaluate the absence of recurrence of persistent AF after a follow up of 12 months after the procedure during a scheduled hospitalization.
DIAGRAM OF RESEARCH European Diagnostic Study, feasibility, non-randomized, multi center
RESEARCH PROCEDURES A trained clinical specialist places 252 dry gelled ECG electrodes on the patient's torso. The 252 ECG electrode array is hooked up to the CardioInsight system and body surface ECG recordings are made during the patient's arrhythmia. The patient is then sent to the radiology department for a CT scan (no contrast) to image both the heart and electrodes on the patient's torso. A trained clinical specialist from CardioInsight then segments the CT DICOM images from the CT scan to obtain epicardial anatomy and establish heart-torso geometry.
The electrograms are processed by the system to produce movies of fibrillatory activity (both focal activity, and rotor activity).
PROCEDURAL ENDPOINTS Primary endpoint: Acute AF termination to atrial tachycardia or sinus rhythm
Secondary outcome criteria:
- Reduction in RF time compared to standard of care (historical control - comparable patient population)
- Reduction in procedure time compared to standard of care (historical control - comparable patient population)
- Freedom from persistent AF at the end of the 12 months F/U period STUDY SIZE
The sample size was estimated at 100 patients, with up to 20 patients per center STUDY CENTERS 8 Centers :
- Brugmann - Brussels (Belgium)
- Clinique Pasteur - Toulouse (France)
- Medizinische Klinik und Poliklinik - Mainz (Germany)
- University ed Herzzentrum Freiburg Bad Kozingen (Germany)
- Deutsches Herzzentrum München, Munich (Germany)
- Kerkhoff Klinik, Bad Nauheim, (Germany)
- Sint-Jan Sint-Franciscus Xaverius, Brugge (Belgium)
- Clinique Ambroise Paré, Paris, France
EXPECTED OUTCOME In patients referred for ablation of persistent AF, ECG mapping data will be correlated to the invasive procedure. It is expected that procedure time will be statistically shorter and total RF energy delivery is expected to be smaller than that of standard of care for AF treatment.
- Conditions
- Atrial Fibrillation
- Medical subject headings
- Atrial Fibrillation
What is being measured
The primary outcome is the main question the study is designed to answer.
radiofrequency duration
Radiofrequency duration necessary to terminate atrial fibrillation and total radiofrequency duration
Measured: 1 day (At the end of the procedure)
Atrial fibrillation termination
Amount of patients with AF termination into sinus rhythm or atrial tachycardia during AF ablation.
Measured: At the time of the procedure of catheter ablation
Secondary outcomes (1)
Atrial fibrillation recurrence
Measured: One year
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted15 Apr 2014 (estimated)
- Study startJan 2014
- Primary completionJul 2015
- Study completion21 Dec 2016
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Atrial FibrillationStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Cohort
- Time perspective
- Prospective
- Enrolment
- 100 participants (actual)
Sponsor and investigators
- Lead sponsor
- Brugmann University Hospital
- Sponsor type
- University, hospital or other
- Collaborators
- Centre Hospitalier Universitaire Brugmann
- Responsible party
- Principal investigator, Pr Sébastien Knecht, Brugmann University Hospital
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT02113761
- Sponsor's protocol ID
- BE77201318160
- Acronym
- AFACART
- Status last verified
- Feb 2017
- First submitted
- 19 Mar 2014
- Last updated
- 2 Feb 2017
- Results posted
- No
- Data monitoring committee
- Yes
Study at a glance
From the registry record, last updated by the sponsor on 2 Feb 2017. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Non Invasive Mapping Before Ablation for Atrial Fibrillation: the Afacart Study.
- ClinicalTrials.gov ID
- NCT02113761
- Acronym / sponsor ID
- AFACART / BE77201318160
- Conditions
- Atrial Fibrillation
- Study type
- Observational
- Recruitment status
- Completed
- Enrolment
- 100 participants (actual)
- Lead sponsor
- Brugmann University HospitalUniversity, hospital or other
- Collaborators
- Centre Hospitalier Universitaire Brugmann
- Study start
- Jan 2014
- Primary completion
- Jul 2015 (actual)
- Study completion
- 21 Dec 2016 (actual)
- First posted
- 15 Apr 2014 (estimated)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
RATIONALE / CONTEXT The ECG records the electrical activity propagating along cardiac cells (from the atria to the ventricles). The standard 12 ECG leads placed on the chest measure the global activation of the heart and do not have the ability to detect small-scale disturbances or to pinpoint ectopic activity. By the 1960s, multiple electrodes were placed around the chest to try to understand the complexity of the distribution of electrical activity in relation to the single cardiothoracic geometry of each individual. The safety of this method is similar to the ECG but its superiority has been demonstrated by the detection of anomalies imperceptible to the standard ECG. The accuracy of the technique in localizing rhythm disturbances is on the order of 5 mm.
OBJECTIVES Main objective: To evaluate the utility of noninvasive mapping during persistent AF electrophysiology procedure
Secondary objectives:
- Compare the effectiveness of noninvasive mapping compared to conventional standard of care methods for AF mapping and ablation procedure.
- Evaluate the absence of recurrence of persistent AF after a follow up of 12 months after the procedure during a scheduled hospitalization.
DIAGRAM OF RESEARCH European Diagnostic Study, feasibility, non-randomized, multi center
RESEARCH PROCEDURES A trained clinical specialist places 252 dry gelled ECG electrodes on the patient's torso. The 252 ECG electrode array is hooked up to the CardioInsight system and body surface ECG recordings are made during the patient's arrhythmia. The patient is then sent to the radiology department for a CT scan (no contrast) to image both the heart and electrodes on the patient's torso. A trained clinical specialist from CardioInsight then segments the CT DICOM images from the CT scan to obtain epicardial anatomy and establish heart-torso geometry.
The electrograms are processed by the system to produce movies of fibrillatory activity (both focal activity, and rotor activity).
PROCEDURAL ENDPOINTS Primary endpoint: Acute AF termination to atrial tachycardia or sinus rhythm
Secondary outcome criteria:
- Reduction in RF time compared to standard of care (historical control - comparable patient population)
- Reduction in procedure time compared to standard of care (historical control - comparable patient population)
- Freedom from persistent AF at the end of the 12 months F/U period STUDY SIZE
The sample size was estimated at 100 patients, with up to 20 patients per center STUDY CENTERS 8 Centers :
- Brugmann - Brussels (Belgium)
- Clinique Pasteur - Toulouse (France)
- Medizinische Klinik und Poliklinik - Mainz (Germany)
- University ed Herzzentrum Freiburg Bad Kozingen (Germany)
- Deutsches Herzzentrum München, Munich (Germany)
- Kerkhoff Klinik, Bad Nauheim, (Germany)
- Sint-Jan Sint-Franciscus Xaverius, Brugge (Belgium)
- Clinique Ambroise Paré, Paris, France
EXPECTED OUTCOME In patients referred for ablation of persistent AF, ECG mapping data will be correlated to the invasive procedure. It is expected that procedure time will be statistically shorter and total RF energy delivery is expected to be smaller than that of standard of care for AF treatment.
Study design
- Observational model
- Cohort
- Time perspective
- Prospective
Who may qualify
- Ages
- 15 years and older
- Sex
- All
- Healthy volunteers
- Accepted
- Age groups
- Child, Adult, Older adult
- Study population
- Patients with persistent atrial fibrillation as described by the Consensus Statement and with an indication for atrial fibrillation catheter ablation.
Key inclusion criteria (5 listed)
- Male or Female Adults (≥18 years old)
- Minors (15-18 years) of both sexes subject to parental consent or legal representative
- Persistent AF ablation refractory to drugs
- Persistent AF (as defined by consensus statement) for ≤ 12 month duration
- Consent signed by the patient after reading the information leaflet
Key exclusion criteria (17 listed)
- Any previous left atrial (LA) ablation
- Any previous LA or RA surgery
- Current intra-cardiac thrombus
- Presence of any pulmonary vein stents
- Presence of any pre-existing pulmonary vein stenosis
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Primary outcome
radiofrequency duration
Time frame: 1 day (At the end of the procedure)
Radiofrequency duration necessary to terminate atrial fibrillation and total radiofrequency duration
Atrial fibrillation termination
Time frame: At the time of the procedure of catheter ablation
Amount of patients with AF termination into sinus rhythm or atrial tachycardia during AF ablation.
1 secondary outcome
Atrial fibrillation recurrence
Time frame: One year
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 2 Feb 2017.
Related trials for Atrial Fibrillation
Active, not recruiting
VOLT CE Mark Study
Atrial Arrhythmia, Atrial Fibrillation
RecruitingObservational study
AI-Based Cardiac Analysis Using 12-Lead and 1-Lead ECG
Heart Failure, Atrial Fibrillation (AF)
RecruitingObservational study
Observational Study of Cardiac Arrhythmias During Treatment With BTK Inhibitors or Venetoclax
Chronic Lymphocytic Leukemia (CLL), Waldenstr(SqrRoot)(Delta)m s Macroglobulinemia
Not yet recruiting
CATCH AF - Atrial Fibrillation Detection in Cryptogenic Stroke
Atrial Fibrillation (AF)
Active, not recruiting
ARIADNE Clinical Trial
Persistent Atrial Fibrillation
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
The record lists no contact. Use the official record to reach the sponsor.
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
An observational study of Atrial Fibrillation, run by Brugmann University Hospital at 1 site in Belgium.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 5 inclusion and 17 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 2 Feb 2017. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in Belgium. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
radiofrequency duration (time frame: 1 day (At the end of the procedure)). The study lists 2 primary outcomes in all. It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 2 Feb 2017.